Drug Profile
mRNA 1443
Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Moderna Therapeutics
- Class Cytomegalovirus vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cytomegalovirus infections
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Cytomegalovirus infections(Combination therapy, Prevention) in USA (Parenteral)
- 28 Jan 2021 ModernaTX completes a phase I trial in Cytomegalovirus infections (Prevention, Combination therapy) in USA (Parenteral) (NCT03382405)
- 28 Dec 2020 No recent reports of development identified for phase-I development in Cytomegalovirus infections(Combination therapy, Prevention) in USA (Parenteral)